Remove Clinic Remove Complication Remove Information Remove Specialization
article thumbnail

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Annals of Family Medicine

The context: Immigrants, particularly those moving from lower to higher-income countries, often exhibit a heightened susceptibility to non-communicable diseases, such as Type 2 diabetes (T2D), which may manifest at an earlier age and present with different complications compared to the native population. 0.83, HR 0.70; 95% CI 0.65-0.76,

article thumbnail

Deprescribing Super Special III: Constance Fung, Emily McDonald, Amy Linsky, and Michelle Odden

GeriPal

Summary Transcript CME Summary Its another deprescribing super special on today’s GeriPal Podcast, where we delve into the latest research on deprescribing medications prescribed to older adults. Join us as we dive deeper into these studies and discuss the implications for clinical practice and patient care. This is Eric Widera.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Future Of Vision And Eye Care

The Medical Futurist

Compared to that, our hearing only processes 11 percent of information, while smell 3.5 Experts even say the eye is an ideal place to start for the first clinical use of CRISPR. Digital contact lenses sound like science fiction: the translucent layer on your eye transmitting special information about your body to an outside device.

article thumbnail

Caring for Patients with Duchenne Muscular Dystrophy in the Emergency Department: A Problem-Based Approach

PEMBlog

Duchenne Muscular Dystrophy (DMD) is a complex and progressive disease requiring highly specialized care, especially in emergency situations. The condition affects multiple organ systems—muscular, cardiac, and respiratory—leading to a myriad of clinical complications.

article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

FDA Law Blog

After a firm submits a 510(k) to FDA, FDA will request still more information after a first-pass review. According to the 2 nd Quarter FY2023 MDUFA V Performance Report , FDA issued a request for additional information (AI request) on the first FDA review cycle for 63% to 68% of 510(k)s submitted in FY2018 to FY2022.

article thumbnail

The Good, Bad, and Ugly side of 510(k)s—HP&M’s Early Experience with the eSTAR Template for 510(k)s

FDA Law Blog

We have made improvements to the content of each of these sections over the years and have included additional information to address other guidance documents and the refuse to accept (RTA) checklist, but the general structure has been constant. In other sections of the template, attachments will be needed to include this type of information.

article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

It depends on the clinical situation. I know this is like, we’re talking about math and so that makes it all a little complicated, but think about it this way. But we still, regardless of how you do this calculation have to temper it with clinical judgment. Eric: All right. The old table, 1.5 Eric: I got two questions.

IT 139